Cellectis plans a Phase 1 investigator-initiated trial (IIT) in China, with preliminary clinical data expected in the second half of 2027. CLLS closed Tuesday at $1.05, up 8.64%.

Cellectis announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate ...

ProJenX, a clinical-stage biotechnology company developing novel, targeted, brain-penetrant therapies for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, ...

APOC3 in a single administration76% triglyceride reduction after a single dose in murine disease modelNEW YORK, Oct.

Lamassu Biotech today announced initial safety and pharmacokinetic data from the ongoing first-in-human Phase 1/2a clinical trial (LB-SA53-101) of SA53, an oral MDM2 inhibitor, at the European Society ...

October 26, 2026) - BCM Resources Corporation (TSXV: B) ("BCM" or the "Company") is pleased to announce that recently completed geophysical surveys are beginning to highlight new prospective targets ...

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human ...

Learn seven design patterns for data science code, from Strategy and Adapter to Command and Proxy, each matched to the ...

Hugging Face's Carbon-X AI model lets researchers analyze DNA using natural language, with lower reported costs and local deployment options for labs.

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...

These data lend support for Faeth’s multi-node strategy, with two upcoming readouts: FTH-PIK-201 topline data in second-line advanced endometrial cancer by year-end 2026 and FTH-PIK-101 interim data ...

How do we make humanoid robots smart? We give them more training data ... and this startup just raised $30M to make it happen ...